BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16797594)

  • 1. The morphological basis of mental dysfunction in Parkinson's disease.
    Jellinger KA
    J Neurol Sci; 2006 Oct; 248(1-2):167-72. PubMed ID: 16797594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.
    Jellinger KA; Attems J
    Acta Neuropathol; 2008 Apr; 115(4):427-36. PubMed ID: 18273624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA
    Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and impact of cerebrovascular lesions in Alzheimer and lewy body diseases.
    Jellinger KA
    Neurodegener Dis; 2010; 7(1-3):112-5. PubMed ID: 20173339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical reappraisal of current staging of Lewy-related pathology in human brain.
    Jellinger KA
    Acta Neuropathol; 2008 Jul; 116(1):1-16. PubMed ID: 18592254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological substrates of mental dysfunction in Lewy body disease: an update.
    Jellinger KA
    J Neural Transm Suppl; 2000; 59():185-212. PubMed ID: 10961431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropathological substrates of Alzheimer's disease and Parkinson's disease.
    Jellinger K
    J Neural Transm Suppl; 1987; 24():109-29. PubMed ID: 3316494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease.
    Jellinger KA; Seppi K; Wenning GK; Poewe W
    J Neural Transm (Vienna); 2002 Mar; 109(3):329-39. PubMed ID: 11956955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease.
    Janvin CC; Larsen JP; Salmon DP; Galasko D; Hugdahl K; Aarsland D
    Mov Disord; 2006 Mar; 21(3):337-42. PubMed ID: 16211595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What causes mental dysfunction in Parkinson's disease?
    Emre M
    Mov Disord; 2003 Sep; 18 Suppl 6():S63-71. PubMed ID: 14502658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism.
    Jellinger KA; Attems J
    Acta Neurol Scand; 2006 Jul; 114(1):38-46. PubMed ID: 16774626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?
    Jellinger KA; Attems J
    Acta Neuropathol; 2006 Sep; 112(3):253-60. PubMed ID: 16804711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.
    Kempster PA; O'Sullivan SS; Holton JL; Revesz T; Lees AJ
    Brain; 2010 Jun; 133(Pt 6):1755-62. PubMed ID: 20371510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intellectual, mnemonic, and frontal functions in dementia with Lewy bodies: A comparison with early and advanced Parkinson's disease.
    Downes JJ; Priestley NM; Doran M; Ferran J; Ghadiali E; Cooper P
    Behav Neurol; 1998; 11(3):173-183. PubMed ID: 11568418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies.
    Beyer MK; Larsen JP; Aarsland D
    Neurology; 2007 Aug; 69(8):747-54. PubMed ID: 17709706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between α-synuclein and tau in Parkinson's disease comment on Wills et al.: elevated tauopathy and α-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218.
    Jellinger KA
    Exp Neurol; 2011 Jan; 227(1):13-8. PubMed ID: 20965169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology.
    Tsuboi Y; Uchikado H; Dickson DW
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S221-4. PubMed ID: 18267239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological basis for dementia in elderly patients with idiopathic Parkinson's disease.
    Yoshimura M
    Eur Neurol; 1988; 28 Suppl 1():29-35. PubMed ID: 3378559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau and alpha-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs.
    Attems J; Quass M; Jellinger KA
    Acta Neuropathol; 2007 Jan; 113(1):53-62. PubMed ID: 17031655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.